Concepedia

Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials

Victor G De Gruttola, Pamela Clax, David L. DeMets, Gregory J. Downing, Susan S. Ellenberg, Lawrence S. Friedman, Mitchell H. Gail, Ross L. Prentice, Janet Wittes, Scott L. Zeger

Controlled Clinical Trials · 2001 · 423 citations · 16 references

DOI

Concepts

References

16

HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time

Alan S. Perelson, Avidan U. Neumann, Martin Markowitz et al. · Science · 1996 · 3.5K citations

, , +16

Surrogate endpoints in clinical trials: Definition and operational criteria

Ross L. Prentice · Statistics in Medicine · 1989 · 2K citations

, , +14

Decay characteristics of HIV-1-infected compartments during combination therapy

Alan S. Perelson, Paulina Essunger, Yunzhen Cao et al. · Nature · 1997 · 1.9K citations

, , +16

Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant

Rhoda Sperling, David E. Shapiro, Robert W. Coombs et al. · New England Journal of Medicine · 1996 · 815 citations

, , +17

Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial

Nathan Shaffer, Rutt Chuachoowong, Philip A. Mock et al. · The Lancet · 1999 · 802 citations

, , +14